Focus on HIV Care

Back to articles

PrEP effective at preventing HIV in high-risk men

KEY POINT

Use of daily pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (Truvada—Gilead) by high-risk men who have sex with men reduced the relative risk of HIV infection by 86% compared with no therapy, according to results of the PROUD study published in Lancet.